Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
Primary Purpose
Insomnia, Brain Injury
Status
Unknown status
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ramelteon
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia focused on measuring sleep disorders, traumatic brain injury
Eligibility Criteria
Inclusion Criteria:
History of traumatic brain injury (TBI) as determined by any of the following at least 1 month prior to study entry:
- Glasgow Coma Scale Score < 15
- Loss of consciousness greater than 5 minutes
- Post traumatic amnesia greater than 30 minutes
- Abnormal neuro-imaging findings after TBI
- Evidence of neurologic deficit as a result of TBI
Endorsement of any of the following by self-report or proxy-report:
- Problems falling or staying asleep
- Daytime sleepiness or fatigue (either cognitive or physical)
- These symptoms must be identified as having an onset after TBI
- Score of > 5 on the Pittsburgh Sleep Quality Index (PSQI)
- Typical bedtime between 8pm and midnight with wake-up time between 6am and 10am on weekdays.
- Must be living in the community
- In the opinion of the Study Team, the participant must be deemed reliable and likely to make all study visits
Exclusion Criteria:
- Bilateral arm fractures, cellulitis or other conditions that prevent safe wearing of the actigraph
- Individuals using other known hypnotic agents (i.e., benzodiazepines, diphenhydramine, zolpidem) will be considered for participation but must have refrained from using sleep medication for two weeks prior to the study and throughout the course of the study
- Movement disorder or spasticity affecting both upper extremities
- Severe pain or history of chronic pain
- Individuals with multiple musculoskeletal injuries
- Taking luvox or fluvoxamine (medication that potentially interact with ramelteon
- Liver disease
- Patients who are ventilator-dependent
- Penetrating head TBI
Sites / Locations
- Kessler Foundation Research Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Rozerem (Ramelteon)
Sugar pill
Arm Description
The primary drug of interest is a melatonin agonist for the treatment of insomnia.
Control condition.
Outcomes
Primary Outcome Measures
Sleep Quality
Sleep Latency (the number of minutes it takes for the participant to fall asleep after getting into bed), and Total Sleep Time (number of minutes asleep between getting into bed for the night and getting out of bed in the morning).
Secondary Outcome Measures
Epworth Sleepiness Scale
Measure of subjective daytime sleepiness.
Cognitive Performance
Performance on a computer-administered continuous performance test.
Full Information
NCT ID
NCT01207050
First Posted
September 21, 2010
Last Updated
September 8, 2014
Sponsor
Kessler Foundation
1. Study Identification
Unique Protocol Identification Number
NCT01207050
Brief Title
Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
Official Title
Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Unknown status
Study Start Date
September 2010 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kessler Foundation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This pilot study proposes to examine the effect of Rozerem on sleep/wake patterns among individuals with Traumatic Brain Injury (TBI) experiencing sleep disturbance, using both objective and subjective measures. It will also show that improvement in sleep/wake patterns resulting from Rozerem will impact daytime functioning using objective and subjective measures.
Detailed Description
Although research has begun to examine sleep quality within the traumatic brain injury (TBI) population, most of the studies found in the research literature utilize subjective, self-report measures that can be problematic in terms of response accuracy when used with populations that have known cognitive deficits (Baños, LaGory, Sawrie, Faught, Knowlton, Prasad, Kuzniecky and Martin, 2004). Because TBI often results in a diminished capacity for self-reflective awareness, obtaining reliable sleep-related information is difficult to do through surveys alone (Fleming, Strong, Ashton, 1996; Vanderploeg, Belanger, Duchnick, and Curtiss, 2007).
A number of studies have attempted to objectify the measurement of sleep quality in TBI rehabilitation by having nursing staff keep an overnight log to document whether the patient was asleep or awake at hourly intervals (Burke, Shah, Schneider, Ahangar, & Al Aladai, 2004; Worthington & Melia, 2006). Because this results in only one single observation point per hour, it misses the nuances of the sleep/wake cycle obtained through more continuous measurement throughout the night and is still somewhat subjective and dependent on the observer's judgment.
Polysomnography, the electrophysiological measurement of sleep, is widely used in the clinical setting to diagnose sleep disorders. Using this more objective measure, Masel and colleagues (2001) found a high prevalence of posttraumatic hypersomnia, sleep apnea-hypopnea syndrome and periodic limb movement disorder that was not identified through self-report measures (Masel, Scheibel, Kimbark, & Kuna, 2001). This illustrates the limitations of self-report questionnaires and highlights the need for more objective measures. However, the high cost and inconvenience of polysomnography, requiring multiple electrodes attached to the face, head, and other parts of the body, make it less practical for research studies.
These limitations of subjective self-report measures and the cost and inconvenience of polysomnography suggest the need for alternative methods of measurement. With the use of an actigraph, a small, highly sensitive, accelerometer (motion detector) worn on the wrist over a period of days, a number of sleep-related variables can be derived through the analysis of motion and rest patterns using a computer algorithm (Coffield & Tryon, 2004). Variables such as sleep latency, total time asleep, and number of nocturnal awakenings derived through actigraphy are comparable to those obtained via polysomnography, and recent research studies demonstrate the validity of actigraph-based sleep/wake estimates among individuals with acquired brain injury (Muller, Czymmek, Thone-Otto, & Von Cramon, 2006; Tweedy & Trost, 2005; Schuiling, Rinkel, Walchenbach, & de Weerd, 2005). Thus, actigraphy represents a means of measurement that will enable the collection of objective data in the comfort of the sleeper's usual environment in a manner that is less invasive and more cost-effective than polysomnography, and more reliable than self-report measures alone.
The most widely researched treatments for sleep disturbance are problematic for individuals with TBI due to their effects on cognition and risk for dependence. With a high prevalence of sleep/wake disorders found among individuals with TBI, Rozerem is a promising treatment option to improve sleep quality that is less likely to exacerbate cognitive sequelae of TBI and less likely to result in dependence.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Brain Injury
Keywords
sleep disorders, traumatic brain injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Rozerem (Ramelteon)
Arm Type
Experimental
Arm Description
The primary drug of interest is a melatonin agonist for the treatment of insomnia.
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Arm Description
Control condition.
Intervention Type
Drug
Intervention Name(s)
Ramelteon
Other Intervention Name(s)
Rozerem
Intervention Description
8mg capsule taken within one half hour of bedtime each night over the three night study period.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
sugar pill
Intervention Description
Control treatment
Primary Outcome Measure Information:
Title
Sleep Quality
Description
Sleep Latency (the number of minutes it takes for the participant to fall asleep after getting into bed), and Total Sleep Time (number of minutes asleep between getting into bed for the night and getting out of bed in the morning).
Time Frame
At third week of treatment
Secondary Outcome Measure Information:
Title
Epworth Sleepiness Scale
Description
Measure of subjective daytime sleepiness.
Time Frame
After completing two weeks of treatment
Title
Cognitive Performance
Description
Performance on a computer-administered continuous performance test.
Time Frame
After completing two weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of traumatic brain injury (TBI) as determined by any of the following at least 1 month prior to study entry:
Glasgow Coma Scale Score < 15
Loss of consciousness greater than 5 minutes
Post traumatic amnesia greater than 30 minutes
Abnormal neuro-imaging findings after TBI
Evidence of neurologic deficit as a result of TBI
Endorsement of any of the following by self-report or proxy-report:
Problems falling or staying asleep
Daytime sleepiness or fatigue (either cognitive or physical)
These symptoms must be identified as having an onset after TBI
Score of > 5 on the Pittsburgh Sleep Quality Index (PSQI)
Typical bedtime between 8pm and midnight with wake-up time between 6am and 10am on weekdays.
Must be living in the community
In the opinion of the Study Team, the participant must be deemed reliable and likely to make all study visits
Exclusion Criteria:
Bilateral arm fractures, cellulitis or other conditions that prevent safe wearing of the actigraph
Individuals using other known hypnotic agents (i.e., benzodiazepines, diphenhydramine, zolpidem) will be considered for participation but must have refrained from using sleep medication for two weeks prior to the study and throughout the course of the study
Movement disorder or spasticity affecting both upper extremities
Severe pain or history of chronic pain
Individuals with multiple musculoskeletal injuries
Taking luvox or fluvoxamine (medication that potentially interact with ramelteon
Liver disease
Patients who are ventilator-dependent
Penetrating head TBI
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Lequerica, PhD
Organizational Affiliation
Kessler Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kessler Foundation Research Center
City
West Orange
State/Province
New Jersey
ZIP/Postal Code
07052
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
15256196
Citation
Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, Kuzniecky R, Martin RC. Self-report of cognitive abilities in temporal lobe epilepsy: cognitive, psychosocial, and emotional factors. Epilepsy Behav. 2004 Aug;5(4):575-9. doi: 10.1016/j.yebeh.2004.04.010.
Results Reference
background
PubMed Identifier
8680388
Citation
Fleming JM, Strong J, Ashton R. Self-awareness of deficits in adults with traumatic brain injury: how best to measure? Brain Inj. 1996 Jan;10(1):1-15. doi: 10.1080/026990596124674.
Results Reference
background
PubMed Identifier
18075951
Citation
Vanderploeg RD, Belanger HG, Duchnick JD, Curtiss G. Awareness problems following moderate to severe traumatic brain injury: Prevalence, assessment methods, and injury correlates. J Rehabil Res Dev. 2007;44(7):937-50. doi: 10.1682/jrrd.2006.12.0163.
Results Reference
background
Citation
Burke DT, Shah MK, Schneider JC, Ahangar B, Al Aladai S. Sleep-wake patterns in brain injury patients in an acute inpatient rehabilitation hospital setting. The Journal of Applied Research 4(2):239-244, 2004.
Results Reference
background
PubMed Identifier
16537274
Citation
Worthington AD, Melia Y. Rehabilitation is compromised by arousal and sleep disorders: results of a survey of rehabilitation centres. Brain Inj. 2006 Mar;20(3):327-32. doi: 10.1080/02699050500488249.
Results Reference
background
PubMed Identifier
11689971
Citation
Masel BE, Scheibel RS, Kimbark T, Kuna ST. Excessive daytime sleepiness in adults with brain injuries. Arch Phys Med Rehabil. 2001 Nov;82(11):1526-32. doi: 10.1053/apmr.2001.26093.
Results Reference
background
PubMed Identifier
15600222
Citation
Coffield TG, Tryon WW. Construct validation of actigraphic sleep measures in hospitalized depressed patients. Behav Sleep Med. 2004;2(1):24-40. doi: 10.1207/s15402010bsm0201_3.
Results Reference
background
PubMed Identifier
16421064
Citation
Muller U, Czymmek J, Thone-Otto A, Von Cramon DY. Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. Brain Inj. 2006 Feb;20(2):157-60. doi: 10.1080/02699050500443467.
Results Reference
background
PubMed Identifier
15677579
Citation
Schuiling WJ, Rinkel GJ, Walchenbach R, de Weerd AW. Disorders of sleep and wake in patients after subarachnoid hemorrhage. Stroke. 2005 Mar;36(3):578-82. doi: 10.1161/01.STR.0000154862.33213.73. Epub 2005 Jan 27.
Results Reference
background
PubMed Identifier
16177597
Citation
Tweedy SM, Trost SG. Validity of accelerometry for measurement of activity in people with brain injury. Med Sci Sports Exerc. 2005 Sep;37(9):1474-80. doi: 10.1249/01.mss.0000177584.43330.ae.
Results Reference
background
Links:
URL
http://www.kesslerfoundation.org
Description
Click here for further information about this study
Learn more about this trial
Effect of Rozerem on Sleep Among People With Traumatic Brain Injury
We'll reach out to this number within 24 hrs